DrugPatentWatch Database Preview

EXONDYS 51 Drug Profile

« Back to Dashboard

Which patents cover Exondys 51, and when can generic versions of Exondys 51 launch?

Exondys 51 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-two patent family members in twenty-three countries.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.

Summary for EXONDYS 51

International Patents:	182
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXONDYS 51
DailyMed Link:	EXONDYS 51 at DailyMed

Generic Entry Opportunity Date for EXONDYS 51

NDA:

206488

Dosage:

SOLUTION;IV (INFUSION)

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EXONDYS 51

Drug Class

Antisense Oligonucleotide

US Patents and Regulatory Information for EXONDYS 51

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes					Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes				Y

International Patents for EXONDYS 51

Country	Document Number	Estimated Expiration
Australia	5752601
Israel	212508
World Intellectual Property Organization (WIPO)	2005065268